News | March 09, 2021
NATCO receives approval for Everolimus tablets for the US market
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
PEL will explore the PLI scheme and apply if its beneficial.
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The commercial production in the SML was started in November 1989.
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Subscribe To Our Newsletter & Stay Updated
